1244 related articles for article (PubMed ID: 28456479)
21. Prevalence of the Preclinical Stages of Alzheimer's Disease in Cognitively Intact Older Adults: The CABLE Study.
Huang SY; Zhu JX; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Tan L; Yu JT
J Alzheimers Dis; 2020; 75(2):483-492. PubMed ID: 32310174
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal tau PET in ageing and Alzheimer's disease.
Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
[TBL] [Abstract][Full Text] [Related]
23. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
[TBL] [Abstract][Full Text] [Related]
24. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
25. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
26. Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults.
Ramanan VK; Castillo AM; Knopman DS; Graff-Radford J; Lowe VJ; Petersen RC; Jack CR; Mielke MM; Vemuri P
JAMA Netw Open; 2019 Oct; 2(10):e1913909. PubMed ID: 31642932
[TBL] [Abstract][Full Text] [Related]
27. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
28. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
30. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
[TBL] [Abstract][Full Text] [Related]
31. The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons.
Vassilaki M; Aakre JA; Kremers WK; Mielke MM; Geda YE; Alhurani RE; Dutt T; Machulda MM; Knopman DS; Vemuri P; Coloma PM; Schauble B; Lowe VJ; Jack CR; Petersen RC; Roberts RO
J Gerontol A Biol Sci Med Sci; 2019 May; 74(6):877-883. PubMed ID: 30124772
[TBL] [Abstract][Full Text] [Related]
32. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Vemuri P; Mielke MM; Lowe V; Senjem ML; Gunter JL; Machulda MM; Gregg BE; Pankratz VS; Rocca WA; Petersen RC
JAMA Neurol; 2015 May; 72(5):511-9. PubMed ID: 25775353
[TBL] [Abstract][Full Text] [Related]
33. Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
Roberts RO; Knopman DS; Syrjanen JA; Aakre JA; Vassilaki M; Kremers WK; Mielke MM; Machulda MM; Graff-Radford J; Geda YE; Vemuri P; Lowe V; Jack CR; Petersen RC
Neurology; 2017 Nov; 89(20):2039-2048. PubMed ID: 29030451
[TBL] [Abstract][Full Text] [Related]
34. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
35. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
[TBL] [Abstract][Full Text] [Related]
36. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
[TBL] [Abstract][Full Text] [Related]
37. Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging.
Wennberg AMV; Savica R; Hagen CE; Roberts RO; Knopman DS; Hollman JH; Vemuri P; Jack CR; Petersen RC; Mielke MM
J Am Geriatr Soc; 2017 Apr; 65(4):792-799. PubMed ID: 27869301
[TBL] [Abstract][Full Text] [Related]
38. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease.
Senda M; Ishii K; Ito K; Ikeuchi T; Matsuda H; Iwatsubo T; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikari Y; Niimi Y; Arai H; Tamaoka A; Arahata Y; Itoh Y; Tachibana H; Ichimiya Y; Washizuka S; Odawara T; Ishii K; Ono K; Yokota T; Nakanishi A; Matsubara E; Mori H; Shimada H
J Prev Alzheimers Dis; 2021; 8(4):495-502. PubMed ID: 34585225
[TBL] [Abstract][Full Text] [Related]
39. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
40. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
